Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2021 | Optimizing chemotherapy combinations for AML

Stéphane de Botton • 14 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Ivosidenib

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the optimization of chemotherapy combinations for the treatment of acute myeloid leukemia (AML), highlighting the importance of considering the safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Stéphane de Botton

Updates on established therapies in AML
19:03
Updates on established therapies in AML
Stéphane de Botton • 20 Sep 2025
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
3:52
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
Stéphane de Botton • 28 Nov 2022
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
6:53
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
Stéphane de Botton • 28 Nov 2022
Treatment strategies for patients with AML who possess a FLT3 mutation
2:15
Treatment strategies for patients with AML who possess a FLT3 mutation
Stéphane de Botton • 28 Nov 2022

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Stéphane de Botton • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Stéphane de Botton • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Stéphane de Botton • 6 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Stéphane de Botton • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals